Hi Jack......just wondered about this trial as it is also recruiting here in the States at Hopkins, MSK, and MD Anderson. But as i understand it..it is a double blind trial......does that mean you may not receive the Urocidin?
The trial will enrol approximately 800 patients and is a double-blind, randomized trial.
About MCC
MCC is a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. It is formulated as Urocidin(TM) for the treatment of bladder cancer, where it is administered by trans-urethral catheter directly into the bladder, coming into contact with immune system cells and bladder cancer cells. MCC is undergoing preclinical evaluation as a treatment for peritoneal carcinomatosis associated with colon and ovarian cancer
Just curious........Pat